Skip to main content

Security report for sobi.com

Sobi · Healthcare · Sweden

Medium risk. 2 critical or high findings in GDPR outside view and SSL/TLS.

Security score

68/100

Risk levelMedium

0–100, higher is better. How it is calculated

Sobi is an established international biopharmaceutical company specializing in innovative treatments for rare diseases. The company maintains a strong market position with a comprehensive pipeline and global outreach, targeting patients, healthcare professionals, and investors. Their website reflects a mature digital presence with professional design, clear navigation, and compliance with privacy regulations. Technically, the site is built on Drupal CMS with modern JavaScript libraries and frameworks, ensuring good performance and mobile optimization. Security posture is strong with HTTPS enforcement and cookie consent mechanisms, though explicit security policies and vulnerability disclosures are absent. Overall, the site demonstrates high professionalism and trustworthiness, supporting Sobi's business credibility in the healthcare sector.

Scanned

NIS2 and GDPR posture

GDPR outside view
63/ 100 · Medium
Checks completed
7of 7

NIS2 Art. 21(2)

  1. (a) Risk analysis and security policies: Not visible from outside
  2. (b) Incident handling: One indicator
  3. (c) Business continuity, backups and crisis management: Not visible from outside
  4. (d) Supply chain security: Not visible from outside
  5. (e) Secure acquisition, development and maintenance, including vulnerability handling: Partly checked
  6. (f) Assessing the effectiveness of security measures: Not visible from outside
  7. (g) Cyber hygiene and security training: Not visible from outside
  8. (h) Cryptography and encryption: Partly checked
  9. (i) HR security, access control and asset management: One indicator
  10. (j) Multi-factor authentication and secured communications: Not visible from outside

This scan rated NIS2 with an earlier keyword method that is no longer shown; rescan for the per-article view. Risk management, continuity, supply chain, training, MFA, management oversight (Art. 20) and incident reporting (Art. 23) need internal evidence, and Guard cannot tell whether NIS2 applies to this organisation.

GDPR is indicative only, based on publicly visible signals: Articles 7, 12, 13 and 32 of Regulation (EU) 2016/679 and Article 5(3) of the ePrivacy Directive. Not a certification or legal assessment.

Priority findings

2 findings rated critical or high. Fix these first.

  1. GDPR outside view

    These are the privacy signals visitors and data protection authorities look for under GDPR.

    • Critical

      No HTTPS encryption

      GDPR requires appropriate security measures for personal data

      What to do: Implement SSL/TLS certificate for HTTPS

  2. SSL/TLS

    TLS encrypts the connection and proves the site is really yours. Weak or expiring certificates trigger browser warnings and put traffic at risk.

    • Critical

      No HTTPS Encryption

      Website does not use HTTPS encryption, making all data transmission vulnerable to interception

      What to do: Implement SSL/TLS certificate and redirect all HTTP traffic to HTTPS

Need hands-on remediation? Email guard@offseq.com

Keep watching sobi.com

This scan found 13 issues across 6 checks. Monitoring re-runs those checks daily, emails you when something material changes and records each fix, so you can show progress.

Daily monitoring

Recommended

€25per month

  • TLS certificates and expiry
  • DNS records
  • SPF, DKIM and DMARC
  • Security headers
  • GDPR and NIS2 posture
  • Exposed services
  • Third-party trackers
  • Security score drift

Email alerts on material changes and an exportable JSON history of every change.

Billed monthly to your card. Cancel anytime. The full timeline opens with your unlock code.

Full report

€39.90one-time

  • The complete analysis as a PDF you can cite
  • Email delivery with an unlock code
  • Lifetime access to this report

Prices incl. 21% VAT. Secure checkout by Mollie; sold by SEQ SIA, Latvia.

Results by check

Each check with its score, findings and the evidence it collected.

How this score is calculated

The security score runs 0–100, higher is better. It is the plain average of the security checks that completed in this scan, each counted equally. A check that could not run is left out: it counts neither as a pass nor as a fail.

Counted in this score

SSL/TLS
0
Security headers
70
Email security
85
DNS health
90
Network security
100
GDPR outside view
63
Average
68

Not counted

  • NIS2 outside view: Re-weights evidence from the TLS, email, DNS, network and hygiene checks, so counting it would count that evidence twice. Shown on its own.
  • OffSeq Observations: An AI reading of the site, useful context but not reproducible evidence. Shown on its own.

Findings that cap the score at 49

Each of these is serious on its own, so while any is present the site cannot rate better than high risk, however good the other checks are.

  • The certificate is not trusted by browsers
  • The website is not served over HTTPS
  • A database, remote desktop, file-sharing or Telnet service is reachable from the internet
  • The page loads a script from a compromised source
  • The domain registration has expired
  • SPF authorises every server to send mail as the domain

Partial scans

When the site blocks Guard or most checks cannot run, the score covers only the checks that ran (usually DNS and email), is capped at 75 and is shown as partial, without a risk level.

Risk levels

  • Critical0–25
  • High26–49
  • Medium50–75
  • Low76–100

Technical appendix

Business context, site observations and technical notes gathered during the scan, and the standards behind each reference.

Business context

Business profile

Sobi operates in the healthcare sector focusing on rare diseases, providing innovative medicines and patient access programs. Their business model revolves around research, development, and commercialization of specialty pharmaceuticals. The company engages with a broad ecosystem including healthcare professionals, patients, investors, and partners. Their digital presence includes investor relations, sustainability initiatives, and global contact points. The company leverages partnerships and regional sites to extend market reach. Content and navigation are tailored to support multiple stakeholder groups, indicating a strategic approach to market positioning and growth.

Security posture

The website employs HTTPS with strong SSL configuration and integrates cookie consent management compliant with GDPR. Security headers are implied but not explicitly confirmed in the HTML. No sensitive data exposure or vulnerable libraries were detected. However, the absence of a published security policy or incident response information suggests room for improvement in transparency and preparedness. The site uses trusted analytics and marketing tools with moderate user tracking. Overall, the security posture is robust but could benefit from enhanced documentation and vulnerability disclosure mechanisms.

Recommendations

  1. Publish a dedicated security policy page outlining security practices and incident response procedures.
  2. Implement and publicly link a vulnerability disclosure policy or security.txt file to encourage responsible reporting.
  3. Verify and explicitly configure security headers such as Content-Security-Policy, X-Frame-Options, and X-Content-Type-Options.
  4. Enhance transparency on data retention policies related to analytics and user tracking.
  5. Regularly audit third-party scripts and libraries to ensure no vulnerabilities are introduced.

Contact details published on the site

Addresses
Legal name
Swedish Orphan Biovitrum AB (publ)
Registration number
556038-9321
Site observations

Automated reading of the public site. Ratings are indicative.

Business

Company
Sobi
Description
Sobi is a specialised international biopharmaceutical company transforming the lives of people with rare diseases.
Key services
Innovative medicines development, Patient access programs, Research and development, Investor relations, Sustainability initiatives
Content quality
excellent
Branding
consistent

Technology

Stack
jQuery, Bootstrap, Highcharts, Slick Carousel, Moment.js, CountUp.js, Drupal CMS
Frameworks
Drupal 10
Platforms
Web
Performance
moderate
Mobile
good
Accessibility
good
SEO
good

Security

Observed score
90/100
Good practices seen
  • HTTPS enforced
  • Cookie consent with granular controls
  • No exposed sensitive data in HTML
  • Use of secure scripts and analytics

Analytics and tracking

Services
Cloudflare Analytics, Custom analytics from analytics.sobi.com
Tracking level
moderate
Privacy practices
good

Advertising

Tracking pixels
Cloudflare Insights
Marketing tools
OneTrust Cookie Consent
Transparency
good

Site quality

Design
excellent
User experience
excellent
Content relevance
excellent
Navigation
excellent
Professionalism
excellent
Trustworthiness
high

Key observations

  1. Website is professionally designed and well-structured
  2. Strong compliance with GDPR and cookie regulations
  3. Clear business focus on rare diseases and biopharmaceutical innovation
  4. Comprehensive contact information and social media presence
  5. No signs of security issues or blocking mechanisms
Technical notes

Notes

The website is built on Drupal 10 CMS, utilizing modern JavaScript libraries including jQuery, Bootstrap, Highcharts, and Slick Carousel for UI components and data visualization. The site is hosted behind Cloudflare, providing CDN and security benefits. Performance is moderate with good mobile responsiveness and accessibility features. SEO is supported by proper meta tags, Open Graph data, and structured JSON-LD schema. The technical infrastructure is solid, though continuous monitoring and optimization could further improve loading times and user experience.
Standards and sources

Reference chips under each finding point to the standard, regulation or specification the finding relates to. They are taken from the official datasets below and mapped conservatively: a finding with no defensible link shows none. NIS2 and GDPR references mark where a finding is relevant evidence, not a compliance verdict. Implementing Regulation (EU) 2024/2690 binds digital infrastructure and digital service providers; for other entities it is the most detailed public reading of the Article 21 measures. WCAG, EN 301 549, European Accessibility Act and Web Accessibility Directive references name the requirement an automated accessibility rule relates to; they are not a conformance verdict.

Retrieved 2026-10-25

Reviews of this site

Share your experience with sobi.com. Every review is verified by email and published after moderation.

Overall rating
Select a rating
4000 characters remaining

We’ll email you to confirm your review and keep your details private.

Community rating

No published reviews yet. Be the first to review sobi.com.

Feedback on this report

Rate this report, add an optional comment, and tell us if you want a security specialist to follow up.

Overall report quality
Select a rating
2000 characters remaining

We only use your feedback to improve Guard reports. Contact details are never shared.